Trial · NCT03893695
Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
NCT03893695, Phase 1, Phase 2, Completed, Suzhou Kintor Pharmaceutical Inc,
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC). Trials, record NCT03893695. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03893695
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
- NCT number
- NCT03893695
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 20 participants, actual
- Lead sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Conditions
- Metastatic Hepatocellular Carcinoma, HCC, Combinations of Drugs; Dependence
- Interventions
- GT90001 and Nivolumab
- First posted
- 2019-03-28
- Last updated
- 2024-02-09
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose-limiting Toxicity(DLT) | 28 days | Each dose cohort will initially include 6 evaluable patients for assessment of toxicity within the 28 days following the first dose of nivolumab and GT90001. |
| Secondary | overall response rate (ORR) | 2 years | To estimate ORR, per RECIST 1.1 assessed by investigator review |
| Secondary | the duration of response (DOR), | 2 years | To evaluate the DOR per RECIST 1.1 assessed by investigator review |
| Secondary | disease control rate (DCR), | 2 years | To evaluate the DCR per RECIST 1.1 assessed by investigator review |
| Secondary | time to response (TTR) | 2 years | To evaluate the TTR per RECIST 1.1 assessed by investigator review |
| Secondary | progression-free survival (PFS) | 2 years | To evaluate the PFS per RECIST 1.1 assessed by investigator review |
| Secondary | maximum concentration (Cmax) | 2 years | Pharmacokinetics |
| Secondary | time that maximum concentration is observed (tmax) | 2 years | Pharmacokinetics |
| Secondary | area under the concentration time-curve from time zero to infinity (AUC0∞) | 2 years | Pharmacokinetics |
| Secondary | area under the plasma concentration-time curve from time zero hours to time (t hrs), (AUC0-t) | 2 years | Pharmacokinetics |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37858184 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03893695
GET https://conductscience.org/api/trials/v1/NCT03893695/registered